Novartis & BDI applying cutting edge tech to clinical trials, drug development

Novartis has partnered with the University of Oxford’s Big Data Institute (BDI) to explore the benefits of data science and artificial intelligence and transform clinical trials and drug development.

The five-year alliance will advance the analysis and interpretation of ultra large and multiple datasets, using artificial intelligence to provide insights into complex diseases.

Cutting edge technologies – such as AI machine learning and advanced analytics – can identify patterns, in ultra large datasets and across multiple datasets and different types of data, that humans cannot.

By increasing the capabilities of spotting patterns and detecting commonalities across different diseases, predictions can be made on how patients will respond to new and existing medicines earlier than is currently possible.

A statement from Novartis said: “Our alliance with the BDI will make use of anonymised data from approximately 5 million patients from the UK and international partner organisations, together with anonymised data captured from relevant Novartis clinical trials.

WWe hope that the combination of our clinical expertise with the BDI’s statistical machine learning technology and experience in statistical analysis will transform the scale and efficiency of clinical research at an unprecedented rate.

“We expect this to result in a better understanding of human disease and the possible routes for improved interventions that will bring benefits to patients.”

Initially, the alliance will focus on two flagship programs aiming to gain scientific insights in multiple sclerosis, dermatology and rheumatology.

By using advanced AI technology to analyse different types of data, the companies hope to improve their understanding of the development and progression of complex diseases like psoriasis and MS.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Related news

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...